Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

2026 data Public-data reference. official source

HNSCC

Open-data reference.

24 US clinical trials · 16 currently recruiting

Active & Recent Trials

RECRUITING 1,500 participants

Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy

University Hospital Freiburg

NCT05337631

RECRUITING Phase 1 523 participants

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Merus B.V.

NCT03526835

RECRUITING Phase 1 450 participants

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Genentech

NCT05581004

RECRUITING Phase 1 250 participants

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

Tubulis

NCT06657222

RECRUITING Phase 1 232 participants

A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors

SparX Biotech(Jiangsu) Co.

NCT06259552

RECRUITING Phase 1 170 participants

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

ALX Oncology

NCT07085091

RECRUITING Phase 1 166 participants

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

Epkin

NCT06789172

RECRUITING Phase 1 160 participants

Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

CJ Bioscience

NCT05877430

RECRUITING Phase 1 150 participants

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

Normunity AccelCo

NCT07182149

RECRUITING Phase 2 72 participants

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Dan Zandberg

NCT04114136

RECRUITING NA 50 participants

High-Resolution PET-CT Imaging for Surgical Margin Visualization

Vanderbilt-Ingram Cancer Center

NCT06915454

RECRUITING Phase 1 41 participants

Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer

VLP Therapeutics

NCT06736379

RECRUITING Phase 1 40 participants

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

Memorial Sloan Kettering Cancer Center

NCT04722523

RECRUITING Phase 2 34 participants

Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC

University of California, Irvine

NCT06693323

RECRUITING Phase 1 30 participants

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

ImmVira Pharma Co.

NCT04370587

RECRUITING Early Phase 1 18 participants

Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer

Vanderbilt-Ingram Cancer Center

NCT06819228

ACTIVE NOT RECRUITING Phase 1 110 participants

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

Compugen

NCT04354246

ACTIVE NOT RECRUITING Phase 1 50 participants

Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC

University of Cincinnati

NCT04340258

ACTIVE NOT RECRUITING Phase 2 37 participants

Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma

Washington University School of Medicine

NCT05980000

ACTIVE NOT RECRUITING Phase 1 18 participants

Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors

AgonOx

NCT05902520

COMPLETED Phase 3 161 participants

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Dan Zandberg

NCT04157985

COMPLETED Phase 2 78 participants

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

University of California, San Diego

NCT03082534

COMPLETED Phase 2 35 participants

De-Escalation Therapy for Human Papillomavirus Negative Disease

University of Chicago

NCT03944915

COMPLETED Phase 1 5 participants

Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC

University of Colorado, Denver

NCT04042935

Phase Distribution

PhaseTrial count
Early Phase 1 16
Phase 2 5
Phase 3 1

Top Sponsors

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Reading the HNSCC Trial Landscape

ClinicalTrials.gov lists 24 US studies indexed under HNSCC, and 16 of those are currently open to recruitment — roughly 67% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.

The phase distribution for HNSCC shows 1 late-stage studies (Phase 3 and Phase 4 combined) alongside 21 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.

Top sponsor activity for HNSCC is led by Dan Zandberg with 2 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 24 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.

Frequently Asked Questions

How many clinical trials are there for HNSCC?

PlainTrial tracks 24 US clinical trials for HNSCC, of which 16 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for HNSCC?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →